BCR-ABL1 Mutation Analysis by Next Generation Sequencing
2008420
Ordering Recommendation
Determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). Test detects all common mutations, including T315I.
Mnemonic
BCRABL NGS
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-12 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavendar (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens. Clotted or serverely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
81403
Components
Component Test Code*Component Chart Name
2008421BCR-ABL1 Mutation by NGS Source
2008422BCR-ABL1 Mutation by NGS Result
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis)
  • ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis)
  • BCR-ABL1 Domain Mutation Analysis
  • BCR-ABL1 Mutation (BCR-ABL1 Domain Mutation Analysis)
  • Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation)
  • Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • TKI Therapy Resistance